Abeona Therapeutics Inc
NASDAQ:ABEO

Watchlist Manager
Abeona Therapeutics Inc Logo
Abeona Therapeutics Inc
NASDAQ:ABEO
Watchlist
Price: 5.36 USD -2.9% Market Closed
Market Cap: 290.5m USD

Operating Margin
Abeona Therapeutics Inc

-20 802.3%
Current
-4 085%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-20 802.3%
=
Operating Profit
-83.2m
/
Revenue
400k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Abeona Therapeutics Inc
NASDAQ:ABEO
280.9m USD
-20 802%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
394.7B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.9B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD
28%
AU
CSL Ltd
ASX:CSL
89.1B AUD
26%
NL
argenx SE
XBRU:ARGX
45.9B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD
8%
No Stocks Found

Abeona Therapeutics Inc
Glance View

Market Cap
280.9m USD
Industry
Biotechnology

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.

ABEO Intrinsic Value
49.95 USD
Undervaluation 89%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-20 802.3%
=
Operating Profit
-83.2m
/
Revenue
400k
What is the Operating Margin of Abeona Therapeutics Inc?

Based on Abeona Therapeutics Inc's most recent financial statements, the company has Operating Margin of -20 802.3%.

Back to Top